Ambar, G. and Chiavegatto, S.. (2009). “Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice.” Genes Brain Behav, 8, 161–173.CrossRefGoogle ScholarPubMed

Andersen, M. B., Werge, T., and Fink-Jensen, A.. (2007). “The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.” J Pharmacol Exp Ther, 321, 1179–1182.CrossRefGoogle ScholarPubMed

Benus, R. F., Bohus, B., Koolhaas, J. M., et al. (1991). “Heritable variation for aggression as a reflection of individual coping strategies.” Experientia, 47, 1008–1019.CrossRefGoogle ScholarPubMed

Bethea, C. L., Phu, K., Kim, A., et al. (2015). “Androgen metabolites impact CSF amines and axonal serotonin via MAO-A and -B in male macaques.” Neuroscience, 301, 576–589.CrossRefGoogle Scholar

Bosboom, J. L., Stoffers, D., and Wolters, E.. (2003). “The role of acetylcholine and dopamine in dementia and psychosis in Parkinson’s disease.” J Neural Transm Suppl, 185–195.CrossRefGoogle Scholar

Bosch, O. J., Dabrowska, J., Modi, M. E., et al. (2016). “Oxytocin in the nucleus accumbens shell reverses CRFR2-evoked passive stress-coping after partner loss in monogamous male prairie voles.” Psychoneuroendocrinology, 64, 66–78.CrossRefGoogle ScholarPubMed

Brunner, H. G., Nelen, M., Breakefield, X. O., et al. (1993). “Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.” Science, 262, 578–580.CrossRefGoogle ScholarPubMed

Buades-Rotger, M. and Gallardo-Pujol, D.. (2014). “The role of the monoamine oxidase A gene in moderating the response to adversity and associated antisocial behavior: a review.” Psychol Res Behav Manag, 7, 185–200.Google ScholarPubMed

de Almeida, R. M., Ferrari, P. F., Parmigiani, S., et al. (2005). “Escalated aggressive behavior: dopamine, serotonin and GABA.” Eur J Pharmacol, 526, 51–64.CrossRefGoogle ScholarPubMed

de Boer, S. F., van der Vegt, B. J. and Koolhaas, J. M.. (2003). “Individual variation in aggression of feral rodent strains: a standard for the genetics of aggression and violence?” Behav Genet, 33, 485–501.CrossRefGoogle ScholarPubMed

de Wied, D., Diamant, M., and Fodor, M.. (1993). “Central nervous system effects of the neurohypophyseal hormones and related peptides.” Front Neuroendocrinol, 14, 251–302.CrossRefGoogle ScholarPubMed

DeLong, M. R. and Wichmann, T.. (2007). “Circuits and circuit disorders of the basal ganglia.” Arch Neurol, 64, 20–24.CrossRefGoogle ScholarPubMed

Di Chiara, G., Bassareo, V., Fenu, S., et al. (2004). “Dopamine and drug addiction: the nucleus accumbens shell connection.” Neuropharmacology, 47 Suppl 1, 227–241.CrossRefGoogle ScholarPubMed

Eme, R. (2010). “Male life-course-persistent antisocial behavior: the most important pediatric mental health problem.” Arch Pediatr Adolesc Med, 164, 486–487.CrossRefGoogle ScholarPubMed

Fava, M., Johe, K., Ereshefsky, L., et al. (2015). “A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.” Mol Psychiatry.Google Scholar

Gallagher, D. and Herrmann, N.. (2014). “Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?” Drugs, 74, 1747–1755.CrossRefGoogle ScholarPubMed

Haney, M. (2005). “The marijuana withdrawal syndrome: diagnosis and treatment.” Curr Psychiatry Rep, 7, 360–366.CrossRefGoogle ScholarPubMed

Hardy, J., Cowburn, R., Barton, A., et al. (1987). “Region-specific loss of glutamate innervation in Alzheimer’s disease.” Neurosci Lett, 73, 77–80.CrossRefGoogle ScholarPubMed

Herrmann, N., Cappell, J., Eryavec, G. M., et al. (2011). “Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer’s disease: an open-label pilot study.” CNS Drugs, 25, 425–433.CrossRefGoogle ScholarPubMed

Hirota, T., Veenstra-Vanderweele, J., Hollander, E., et al. (2014). “Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis.” J Autism Dev Disord, 44, 948–957.CrossRefGoogle ScholarPubMed

Hshieh, T. T., Fong, T. G., Marcantonio, E. R., et al. (2008). “Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence.” J Gerontol A Biol Sci Med Sci, 63, 764–772.CrossRefGoogle ScholarPubMed

Kiecolt-Glaser, J. K., Derry, H. M., and Fagundes, C. P.. (2015). “Inflammation: depression fans the flames and feasts on the heat.” Am J Psychiatry, 172, 1075–1091.CrossRefGoogle ScholarPubMed

Kim, I. H., Rossi, M. A., Aryal, D. K., et al. (2015). “Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine.” Nat Neurosci, 18, 883–891.CrossRefGoogle ScholarPubMed

Kirby, M. and Lawlor, B. A.. (1995). “Biologic markers and neurochemical correlates of agitation and psychosis in dementia.” J Geriatr Psychiatry Neurol, 8 Suppl 1, S2–7.CrossRefGoogle ScholarPubMed

Kumsta, R. and Heinrichs, M.. (2013). “Oxytocin, stress and social behavior: neurogenetics of the human oxytocin system.” Curr Opin Neurobiol, 23, 11–16.CrossRefGoogle ScholarPubMed

Kumsta, R., Hummel, E., Chen, F. S., et al. (2013). “Epigenetic regulation of the oxytocin receptor gene: implications for behavioral neuroscience.” Front Neurosci, 7, 83.CrossRefGoogle ScholarPubMed

Li, J. J. and Lee, S. S.. (2010). “Latent class analysis of antisocial behavior: interaction of serotonin transporter genotype and maltreatment.” J Abnorm Child Psychol, 38, 789–801.CrossRefGoogle ScholarPubMed

Liechti, M. (2015). “Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.” Swiss Med Wkly, 145, w14043.Google ScholarPubMed

Lindenmayer, J. P. (2000). “The pathophysiology of agitation.” J Clin Psychiatry, 61 Suppl 14, 5–10.Google ScholarPubMed

Liu, C. S., Chau, S. A., Ruthirakuhan, M., et al. (2015). “Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease.” CNS Drugs, 29, 615–623.CrossRefGoogle ScholarPubMed

Maes, M., Scharpe, S., Verkerk, R., et al. (1995). “Seasonal variation in plasma L-tryptophan availability in healthy volunteers: relationships to violent suicide occurrence.” Arch Gen Psychiatry, 52, 937–946.CrossRefGoogle ScholarPubMed

Maneta, E. and Garcia, G.. (2014). “Psychiatric manifestations of Anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications.” Psychosomatics, 55, 37–44.CrossRefGoogle ScholarPubMed

Meldrum, B. S. (2000). “Glutamate as a neurotransmitter in the brain: review of physiology and pathology.” J Nutr, 130, 1007S–1015S.CrossRefGoogle ScholarPubMed

Miczek, K. A., Fish, E. W., De Bold, J. F., et al. (2002). “Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.” Psychopharmacology (Berl), 163, 434–458.CrossRefGoogle ScholarPubMed

Myers, A. J., Williams, L., Gatt, J. M., et al. (2014). “Variation in the oxytocin receptor gene is associated with increased risk for anxiety, stress and depression in individuals with a history of exposure to early life stress.” J Psychiatr Res, 59, 93–100.CrossRefGoogle ScholarPubMed

Nichols, C. D. and Sanders-Bush, E.. (2004). “Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins.” J Neurochem, 90, 576–584.CrossRefGoogle ScholarPubMed

O’Driscoll, K. and Leach, J. P.. (1998). “‘No longer Gage’: an iron bar through the head. Early observations of personality change after injury to the prefrontal cortex.” BMJ, 317, 1673–1674.Google Scholar

Picciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., et al. (2015). “Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states.” Neuropharmacology, 96, 235–243.CrossRefGoogle ScholarPubMed

Porsteinsson, A. P., Keltz, M. A. and Smith, J. S.. (2014). “Role of citalopram in the treatment of agitation in Alzheimer’s disease.” Neurodegener Dis Manag, 4, 345–349.CrossRefGoogle ScholarPubMed

Radley, J. J., Kabbaj, M., Jacobson, L., et al. (2011). “Stress risk factors and stress-related pathology: neuroplasticity, epigenetics and endophenotypes.” Stress, 14, 481–497.CrossRefGoogle ScholarPubMed

Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., et al. (2005). “Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.” J Neurosci, 25, 1904–1913.CrossRefGoogle ScholarPubMed

Sachdev, P. and Kruk, J.. (1996). “Restlessness: the anatomy of a neuropsychiatric symptom.” Aust N Z J Psychiatry, 30, 38–53.CrossRefGoogle ScholarPubMed

Sachdev, P. S., Chen, X., Joscelyne, A., et al. (2007). “Amygdala in stroke/transient ischemic attack patients and its relationship to cognitive impairment and psychopathology: the Sydney Stroke Study.” Am J Geriatr Psychiatry, 15, 487–496.CrossRefGoogle ScholarPubMed

Shibuya-Tayoshi, S., Tsuchiya, K., Seki, Y., et al. (2005). “Presenile dementia mimicking Pick’s disease: an autopsy case of localized amygdala degeneration with character change and emotional disorder.” Neuropathology, 25, 235–240.CrossRefGoogle ScholarPubMed

Siegel, A. and Victoroff, J.. (2009). “Understanding human aggression: new insights from neuroscience.” Int J Law Psychiatry, 32, 209–215.CrossRefGoogle ScholarPubMed

Siegel, J. Z. and Crockett, M. J.. (2013). “How serotonin shapes moral judgment and behavior.” Ann N Y Acad Sci, 1299, 42–51.CrossRefGoogle ScholarPubMed

Siepmann, T., Penzlin, A. I., Kepplinger, J., et al. (2015). “Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence.” Brain Behav, 5, e00373.CrossRefGoogle ScholarPubMed

Smith, C. C., Gibbs, T. T., and Farb, D. H.. (2014). “Pregnenolone sulfate as a modulator of synaptic plasticity.” Psychopharmacology (Berl), 231, 3537–3556.CrossRefGoogle ScholarPubMed

Taft, C. T., Creech, S. K., and Kachadourian, L.. (2012). “Assessment and treatment of posttraumatic anger and aggression: a review.” J Rehabil Res Dev, 49, 777–788.CrossRefGoogle ScholarPubMed

Takahashi, A., Shiroishi, T., and Koide, T.. (2014). “Genetic mapping of escalated aggression in wild-derived mouse strain MSM/Ms: association with serotonin-related genes.” Front Neurosci, 8, 156.CrossRefGoogle ScholarPubMed

Takahashi, A., Sugimoto, H., Kato, S., et al. (2015). “Mapping of genetic factors that elicit intermale aggressive behavior on mouse chromosome 15: intruder effects and the complex genetic basis.” PLoS One, 10, e0137764.CrossRefGoogle ScholarPubMed

Terracciano, A., Esko, T., Sutin, A. R., et al. (2011). “Meta-analysis of genome-wide association studies identifies common variants in CTNNA2 associated with excitement-seeking.” Transl Psychiatry, 1, e49.CrossRefGoogle ScholarPubMed

Trzepacz, P. T., Yu, P., Bhamidipati, P. K., et al. (2013). “Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer’s disease.” Alzheimers Dement, 9, S95–S104 e101.CrossRefGoogle ScholarPubMed

Van den Elsen, G. A., Ahmed, A. I., Verkes, R. J., et al. (2015). “Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial.” Neurology, 84, 2338–2346.CrossRefGoogle ScholarPubMed

Van der Jeugd, A., Blum, D., Raison, S., et al. (2013). “Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia.” Behav Brain Res, 242, 34–39.CrossRefGoogle ScholarPubMed

Van der Mast, R. C. and Fekkes, D.. (2000). “Serotonin and amino acids: partners in delirium pathophysiology?” Semin Clin Neuropsychiatry, 5, 125–131.Google ScholarPubMed

Volk, D. W., Chitrapu, A., Edelson, J. R., et al. (2015). “Molecular mechanisms and timing of cortical immune activation in schizophrenia.” Am J Psychiatry, 172, 1112–1121.CrossRefGoogle ScholarPubMed

Waters, E., Morrall, M. C. and Murdoch-Eaton, D.. (2010). “Archimedes. Question 3. Should carbamazepine be administered to manage agitation and aggressive behaviour following paediatric acquired brain injury?” Arch Dis Child, 95, 950–952.CrossRefGoogle ScholarPubMed

Wilkinson, S. T., Stefanovics, E. and Rosenheck, R. A.. (2015). “Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.” J Clin Psychiatry, 76, 1174–1180.CrossRefGoogle ScholarPubMed

Wong, P., Chang, C. C., Marx, C. E., et al. (2012). “Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice.” PLoS One, 7, e51455.CrossRefGoogle ScholarPubMed

Zalcman, S. S. and Siegel, A.. (2006). “The neurobiology of aggression and rage: role of cytokines.” Brain Behav Immun, 20, 507–514.CrossRefGoogle ScholarPubMed

Zhang, Y., Traskman-Bendz, L., Janelidze, S., et al. (2012). “Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence.” J Clin Psychiatry, 73, 1069–1076.CrossRefGoogle ScholarPubMed

Ziv, L., Muto, A., Schoonheim, P. J., et al. (2013). “An affective disorder in zebrafish with mutation of the glucocorticoid receptor.” Mol Psychiatry, 18, 681–691.CrossRefGoogle ScholarPubMed